resectable pancreatic cancer
Conditions
Interventions
Regimen of the chemotherapy: 1000mg/2 of Gemcitabine and 125mg/m2 of nab-Paclitaxel are administered. Schedule: Gemcitabine and nab-Paclitaxel are administered once a week concurrently. A cycle is c
Sponsors
Hirosaki University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adenocarcinoma and adenosquamous carcinoma is confirmed pathologically. 2. No distant metastases are pointed out. 3. Resectability is diagnosed as "Resectable" according to General Rules for the Study of Pancreatic Cancer, 7th edition. 4. Radical surgery is tolerable. 5. No treatment history of pancreatic cancer. 6. Patient over 20 years old. 7. Good performance status (ECOG PS 0-1). 8. Appropriate biliary drainage has been performed when the patient had obstructive jaundice. 9. Main organ's functions are maintained. 10. Informed consent has been obtained in writing by the patient about the trial participation.
Exclusion criteria
Exclusion criteria: 1. Patient with the treatment history of gemcitabine or nab/paclitaxel. 2. R0 resection is judged to be impossible. 3. Patient with sever diarrhea. 4. Patient with sever ascites and pleural effusion. 5. Patient with active other cancer. 6. Patient with sever coexisting disease. 7. Patients with active infectious disease. 8. Patient with remarkable abnormal electrocardiogram or sever cardiac disorder. 9. Patient with severe psychiatric disorder. 10. Pregnant female, lactating female, female who might be pregnant, female who hopes to be pregnant, and male who hopes the partner's pregnancy. 11. Patient with the history of sever medication allergy. 12. Patient with continuous systemic administration of the steroid. 13. Patient with contraindication of gemcitabine and nab-paclitaxel. 14. Patient where the attending doctor judged unsuitable for safely carrying out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| relapse-free survival time | — |
Secondary
| Measure | Time frame |
|---|---|
| completion rate of preoperative chemotherapy, over-all survival time, down-staging rate, R0 resection rate, adverse event rate, anti-tumor efficacy | — |
Countries
Japan
Contacts
Public ContactKeinosuke Ishido
Hirosaki University Graduate School of Medicine Department of Gastroenterological Surgery
Outcome results
None listed